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Next-generation sequencingThe gut microbiome, which hosts up to 1000 bacterial species that encode about 5 million genes, performmany
of the functions required for host physiology and survival. Consequently, it is also known as “our forgotten
organ”. The recent development of next-generation sequencing technologies has greatly improvedmetagenomic
research. In particular, it has increased our knowledge about themicrobiome and itsmutually beneﬁcial relation-
ships with the human host. Microbial colonization begins immediately at birth. Although inﬂuenced by a variety
of stimuli, namely, diet, physical activity, travel, illness, hormonal cycles and therapies, the microbiome is practi-
cally stable in healthy adults. This suggests that themicrobiome plays a role in themaintenance of a healthy state
in adulthood. Quantitative and qualitative alterations in the composition of the gut microbiome could lead to
pathological dysbiosis, and have been related to an increasing number of intestinal and extra-intestinal diseases.
With the increase in knowledge about gut microbiome functions, it is becoming increasingly more possible to
develop novel diagnostic, prognostic and, most important, therapeutic strategies based on microbiome
manipulation.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. The humanmicrobiome: general facts and its interactionwith the
human host
Amicrobiota is deﬁned as the community of microrganisms, includ-
ing bacteria, archaea, viruses, and some unicellular eukaryotes, living in
a speciﬁc environment. A microbiome, on the other hand, is the entire
collection of all the genomic elements of a speciﬁc microbiota, whereas
metagenomics is the ﬁeld of molecular research that studies the
complexity of microbiomes.
In this optics, and considering the human body as an environment,
the human microbiota is the entire collection of microorganisms living
on the surface and inside our body (Table 1) [1–4]. These communities
are important for human physiology, immune system development,
digestion and detoxiﬁcation reactions. In fact, some of these microor-
ganisms residing in the gut encode proteins involved in functions
important for the host’s health, such as enzymes required for the hydro-
lysis of otherwise indigestible dietary compounds, and the synthesis of
vitamins [5,6]. Consequently, we have two genomes, one inherited
from our parents and the other acquired, i.e., the microbiome. ThisS, next-generation sequencing;
vanzate, and Dipartimento di
9, Via Sergio Pansini 5, 80131
. This is an open access article underconcept is the basis of the deﬁnition of humans as “superorganisms”
[7]. The most important difference between these two genomes is
that, while the inherited genome remains almost stable during lifetime,
the microbiome is extremely dynamic and can be inﬂuenced by a
number of factors, among which, age [8], diet [9,10], hormonal cycles
[11], travel [12], therapies [13], and illness [13].
Humans are born sterile and microbial colonization begins immedi-
ately at birth. The establishment of the infant microbiota appears to be
mainly inﬂuenced by the type of delivery and the subsequent feeding
practices [14–17]. In addition, a number of studies have identiﬁed a
high intra-individual variability in the infant microbiota composition,
especially during the ﬁrst year of life; it assumes a more adult-like
pattern when the host reaches 3 years of age [13–16]. A longitudinal
microbiome analysis, carried out on different biological samples collect-
ed from the same healthy adults at different time points, has shown not
only the presence of speciﬁc microbial signatures in the body sites
evaluated, but also a great intra-individual variability over time [18].
Aging is associated with a number of physiological and biological
modiﬁcations, and indeed, it has been recently reported that the
microbiome composition differs between adults and the elderly [19].
Most of the human adult microbiota lives in the gut. Only in the
human colon does microbial cell density exceed 1011 cells/g contents,
being equivalent to 1–2 kg of body weight [20]. In addition, it has
been estimated that the human gut microbiome accounts for more
than 5 million different genes [21]. It is now known that over 1,000
different species colonize the human gut [22], all of which belong to athe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Human microbiota composition across the ﬁve most extensively studied body sites.
Interestingly, the oral and gut microbiota have the highest microbial diversity, while the
urogenital tract has the smallest bacterial diversity [See references 1–4].
Human microbiota
(10 times more microbial than human cells: 1014 vs 1013)
Human
microbial
habitats
Most represented Phyla and their relative
abundance (%)
Number of
species
Oral cavity Firmicutes (36.7), Bacteroidetes (17.3),
Proteobacteria (17.1), Actinobacteria (11.9),
Fusobacteria (5.2)
N500
Skin Actinobacteria (52), Firmicutes (24.4),
Proteobacteria (16.5), Bacteroidetes (6.3)
~300
Airways Actinobacteria (55), Firmicutes (15),
Proteobacteria (8), Bacteroidetes (3)
N500
Gut Firmicutes (38.8), Bacteroidetes (27.8),
Actinobacteria (8.2), Proteobacteria (2.1)
N1000
Urogenital
tracta
Firmicutes (83), Bacteroidetes (3),
Actinobacteria (3)
~150
a Mainly female.
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and Actinobacteria, while Proteobacteria, Fusobacteria, Cyanobacteria and
Verrucomicrobia are usually lesswell represented [6]. Remarkably, given
this high inter-individual variability in the gut microbiota composition,
a core gut microbiome, shared by healthy adults, has been identiﬁed,
which suggests that it plays a role in the maintenance of health status
(Table 2) [23]. To date, a number of functions have been associated to
the core microbiome, including polysaccharide digestion, immune
system development, defense against infections, synthesis of vitamins,
fat storage, angiogenesis regulation, and behavior development [5,6,
24,25]. Interestingly, genes encoded by the human core microbiome
encode proteins required for host survival, but not present in the
human genome, this ﬁnding led to the deﬁnition of the microbiome as
“our forgotten organ” [26].
In this scenario, alterations of the human gut microbiome can play a
role in disease development. It is feasible that as we learn more about
microbiome composition and functions in healthy individuals, and
their modiﬁcations associated with speciﬁc disease, it will become
possible to use the microbiome as a novel target for diagnostic andTable 2
Human gut microbiota composition throughout life. In healthy conditions, microbial
diversity and richness increase with age reach their highest complexity during adulthood.
Despite inter- and intra-individual variations, the gut microbiome is practically stable in
healthy adults. In the elderly, as in infants, the gut microbiome is more unstable and also
has a lower diversity with respect to adults [49].
Phylum level microbial
composition
(from the most to the less
represented)
Modifying factors
Infant (up to
2–3 years)
Actinobacteria,
Proteobacteria, Firmicutes,
Bacteroidetes
− Vaginal vs caesarian delivery
− Gestational age
− Infant hospitalization
− Breast vs formula fed
− Age at solid food introduction
− Malnutrition
− Antibiotic treatments
Adult Firmicutes, Bacteroidetes,
Actinobacteria, Proteobacteria
− Diet
− Hormonal cycles
− Travel
− Therapies
− Illness
Elderly (N70
years)
Firmicutes, Actinobacteria,
Bacteroidetes, Proteobacteria
− Lifestyle changes
− Nutritional changes
− Increased susceptibility to infec-
tions and inﬂammatory diseases
− Use of more medicationstherapeutic applications. Here, we review the main techniques now
available for metagenomic studies, and the association between
microbial dysbiosis and the development of speciﬁc diseases.
2. Next-generation sequencing-based approaches for the study of
the human microbiome
2.1. Background
The ﬁrst microbial studies were based on the direct cultivation and
isolation of microbes. Although these methodologies are currently
used also for diagnostic purposes, they are somewhat limited because
the growth conditions used may favor the selection of one or more
species over the others. In addition, it is estimated that up to 99% of
microbes are currently uncultivable [27]. Other methods, such as
quantitative PCR and polyacrylammide gel electrophoresis separation,
are also inﬂuenced by the use of speciﬁc probes for the detection of
speciﬁc bacteria. Therefore, they are not suitable for the study of entire
microbiomes.
Over the past ten years, the rapid development of next-generation
sequencing (NGS) technologies, which increase the throughput of
bases sequenced/run while reducing sequencing costs, has had a major
impact on the ﬁeld of metagenomics. In fact, a speciﬁc microbiome can
be qualitatively and quantitatively characterized in-depth using NGS-
based approaches without the selection bias and constraints associated
with cultivation methods. These technologies are being used also in the
Human Microbiome Project, the aim of which is to obtain a complete
catalogue of the microbes living in the various districts of the human
body and to deﬁne their functions [6,21,22].
Although NGS-based strategies have greatly improved our knowl-
edge in the ﬁeld of metagenomics, they have some limitations. In fact,
some technical issues still need to be resolved, andNGS-based strategies
depend largely on continuously updated databases, bioinformatic tools,
and functional information. The combination of several analytic strate-
gies, including traditional cultivationmethods, to characterize the geno-
mic and metabolic properties of speciﬁc bacteria will provide further
insight into the role of the microbiota, and will also help to identify
novel candidate targets for disease diagnosis and treatment.
Below we brieﬂy review the NGS-based strategies that can be used
for metagenomic purposes (Fig. 1).
2.2. Shotgun sequencing
Shotgun sequencing is the analysis of an entire microbial communi-
ty. It is based on the extraction of genomic DNA directly from an
environmental sample; this DNA is used to prepare an NGS library for
downstream high-throughput sequencing. Subsequent data analysis,
performed with speciﬁc bioinformatic tools, is required to assign the
obtained reads to both the host and its microbial components, and to
perform genome assembly. The great advantage of this method is that
it avoids both the cultivation and PCR steps since the DNA is directly
analyzed. It can also identify bacteria up to species level (the complete,
or almost complete, genome can be assembled), and is also used for
virome analysis (there is no universal tag for virus analysis). However,
the correct assignment of sequencing reads is often difﬁcult due to
limitations in the databases currently available as reference. Moreover,
genome assembly could be ﬂawed especially in the case of less
abundant and/or closely related species. Function assignment may be
difﬁcult, and could also be ambiguous. Finally, some biases could be
related to the method used for DNA extraction [28].
2.3. 16S rRNA sequencing
Targeted sequencing of speciﬁc genes enables one to study the
microbiome in all its complexity in an easy and cost-effective manner.
All bacteria host the 16S rRNA gene, which is generally used for
Fig. 1. Next Generation sequencing-based approaches for metagenomics. Starting from an environmental sample of interest (1), total DNA and/or RNA are extracted (2). Three different
sample preparation strategies can be used depending on the project aims: 16 s rRNA Sequencing, Shotgun Sequencing, and Metatranscriptomics (3). Usually, the 16S rRNA procedure
allows sample multiplexing while a higher coverage is required for the others. After sequencing (4), speciﬁc bioinformatic pipelines are used for data analysis (5).
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characterized by hypervariable regions spaced by ultra-conserved re-
gions [29]. Therefore, universal primers (by annealing on the conserved
regions) can be used to amplify, in a single PCR reaction, virtually all the
bacteria present in a target environment, and to unequivocally identify
them at the end of sequencing [30]. Although 16S rRNA sequencing has
the advantage of being easy to perform, fast and relatively inexpensive,
DNA extractionmay be biased and the PCRmethodologymay confound
the analysis and produce ambiguous results [28,31]. Also in this case,
the assignment of reads depends on the accuracy of the reference data-
bases used, and the procedure does not produce data about bacterial
functions.2.4. Metatranscriptomics
Metatranscriptomics serves to analyze the entire transcriptome of
an environmental site to obtain a comprehensive view of gene expres-
sion proﬁles and functional data. Several factors affect the large-scale
application of metatranscriptomics, namely, technical issues related to
RNA extraction and storage procedures, RNA quality and quantity and,
most important, the enrichment procedure used to remove rRNAs. In
addition, host contaminations may affect the procedure, and cannot be
removed by the currently available rRNA puriﬁcation methods [32].
Finally, bioinformatic tools for metatranscriptomic data analysis are
still being developed.
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Thewidespread use of the above-mentionedmetagenomic strategies
has increased the need for speciﬁc data analysis pipelines able to inter-
pret the complex NGS data generated, as reviewed elsewhere [33,34].
Various tools for the analysis of 16S NGS reads have been developed
in recent years, andwe previously evaluated the performances of two of
them in the same dataset [35]. Most of thesemethods include both tax-
onomic identiﬁcation and diversity analysis [36–38]. Taxonomic identi-
ﬁcation accuracy is variable and depends not only on the speciﬁc
pipeline used, but also on the portion of the 16S rRNA sequenced, PCR
biases and the availability of updated databases. In general, taxonomic
assignment is from phylum to genus, while species identiﬁcation is
more difﬁcult [39]. In fact, the 16S rRNA sequencing approach gives a
picture of the entire qualitative and quantitative composition of a
microbiome, but does not provide information about a speciﬁc bacteria
genome and/or functions. In silico tools for the functional prediction of
themostwell studiedmicrobiomes, such as the human gut microbiome
have recently become available [40].Fig. 2. Ileum-associated microbiome composition in a Crohn’s disease patient before (patient-B
16S rRNA next-generation sequencing. (a) Note the reduction of Bacteroidetes and the signiﬁca
trol patient. (b) The heatmap table shows in brownish red the most signiﬁcant alterations; th
(c) Themean ShannonDiversity Index Score shows signiﬁcantly lower values in the patient-BT cShotgun DNA sequencing, which is the NGS sequencing of thewhole
DNA isolated from an environmental sample, generates the sequence of
the host and of all the microbes present in the studied environment,
including bacteria, archaea, fungi and viruses, without culture-related
and PCR-related biases. Speciﬁc tools are available to obtain taxonomic
identiﬁcation up to species and strain levels [41–43]. Besides providing
a more accurate identiﬁcation, with these tools it is possible to make
predictions about functional properties. Various pipelines are available
for this procedure although they still have computational limitations
[44–49]. Metatranscriptomics promises to largely overcome the lack of
knowledge and also the ambiguity related to assignment. Indeed, a
few tools are already available for this kind of analysis although most
depend on the availability of genome reference sequences [50–52].
3. The human microbiome, healthy status and diseases
Various reviews have extensively covered the link between the
human microbiome and state of health [see e.g., 53,54]. In this section
we will only brieﬂy mention some of the most relevant data related toT) and after (patient-AT) nutritional therapy and in a control subject, as characterized by
ntly higher prevalence of Proteobacteria in the patient-BT vs the patient-AT and vs the con-
e numerical ﬁgures indicate the number of bacterial families sequenced in each patient.
omparedwith values obtained in the patient-AT and in the control subject (*P b 0.05) [69].
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during healthy adulthood, its qualitative and quantitative alterations,
which lead of course to functional modiﬁcations, has been reported in
a number of human diseases [55–58]. In particular, microbial richness,
intended as bacterial diversity, is usually considered an indicator of a
healthy status: reduced bacterial diversity has been related to obesity
and immune-related and inﬂammatory diseases [55–64]. In addition,
as a healthy microbiome composition is required for a number of phys-
iological functions [5,6,24,25], qualitative alterations, especially at level
of the core microbiome, can lead to the development of disease. This
phenomenon has been mostly studied in inﬂammatory bowel diseases
(IBD), including both Crohn’s disease and ulcerative colitis [65–69].
Inﬂammatory bowel diseases are chronic recurrent disease of the
gastrointestinal tract, and are caused by a combination of genetic and
environmental factors, including the gut microbiota. A number of
studies have reported signiﬁcant alterations of gut microbial composi-
tion in IBD patients compared with not affected individuals [65–69].
Not only do IBD patients have an altered rate of Bacteroidetes,
Proteobacteria and Firmicutes colonization, but the bacterial diversity
of their microbiome is generally lower than that of controls. In this
context, we characterized the 16S rRNA ileum-associated microbiome
of a Crohn-affected patient at diagnosis and after nutritional therapy
that reduces gut inﬂammation, and found that the microbial balance
was restored by nutritional therapy; in fact, at follow-up the microbial
balance did not differ between the patient and control (Fig. 2) [69].
Differences in the gut microbiome between obese and not obese sub-
jects have been also reported and extensively reviewed [62–64].
Although it is well recognized that alterations of gut microbiota and gut
permeability can induce the inﬂammatory status typical of obesity, the
speciﬁc microbial changes and the mechanisms by which they act, are
still unclear. The same applies to an increasing number of intestinal and
extra-intestinal diseases [55–58]. Themorewe learn about the gutmicro-
biota and its functions, the betterwewill understand themechanismsun-
derlying a number of diseases, and how to use the microbiota itself as
diagnostic and/or prognostic biomarker. Similarly, greater insight into
the gut microbiota will enable us to develop novel therapeutic strategies
also in the context of an ever more personalized medicine [70].
4. Conclusions and perspectives
Metagenomics has shed considerable light on microbiomes, includ-
ing the human microbiome, and on the complex relationships between
microbes and their hosts. Today, we know that the gut microbiome
plays a role in functions required for the physiology and correct
development of our organs, and that its composition is related to
aging, environmental factors (diet, physical activity, etc.), and patholog-
ical conditions. Understanding the role of speciﬁc microbes will open
the way to novel strategies for disease diagnosis, monitoring and
therapy. The modulation of the gut microbiota to gain a healthy status
is the challenge facing metagenomic research in coming years.
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